SeNostic

SeNostic is a private, pre-revenue diagnostics and drug discovery platform company targeting neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, as well as Type 2 Diabetes. Its proprietary SeedCycler® technology utilizes a protein amplification method, similar to PCR, to detect and analyze disease-specific misfolded protein aggregates (e.g., α-synuclein, amyloid-β) from biofluids. The company aims to serve the high-unmet-need markets of early disease diagnostics, patient stratification for clinical trials, and pre-clinical drug screening, with a business model encompassing device sales, consumables, assays, and recombinant protein reagents.

SeedCycler®: A patented medical device and platform technology that uses protein amplification (similar to PCR) to detect and analyze misfolded protein aggregates (seeds) from biofluids. It applies cyclic shear forces to amplify aggregates, with fluorescence kinetics readouts for analyzing biomarkers like α-synuclein, amyloid-β, tau, TDP-43, and IAPP.

SeNostic competes in the emerging field of seed amplification assays for neurodegenerative diseases, facing competition from academic labs and companies commercializing variations of technologies like RT-QuIC and PMCA. In diagnostics, it must compete against established imaging techniques and emerging blood-based assays from larger diagnostics firms. Its success will depend on demonstrating superior sensitivity, specificity, and platform usability.